Matches in SemOpenAlex for { <https://semopenalex.org/work/W2582243751> ?p ?o ?g. }
- W2582243751 endingPage "1769" @default.
- W2582243751 startingPage "1764" @default.
- W2582243751 abstract "Purpose Sunitinib is a standard initial therapy in metastatic renal cell carcinoma (mRCC), but chronic dosing requires balancing toxicity with clinical benefit. The feasibility and clinical outcome with intermittent sunitinib dosing in patients with mRCC was explored. Patients and Methods Patients with treatment-naïve, clear cell mRCC were treated with four cycles of sunitinib (50 mg once per day, 4 weeks of receiving treatment followed by 2 weeks of no treatment). Patients with a ≥ 10% reduction in tumor burden (TB) after four cycles had sunitinib held, with restaging scans performed every two cycles. Sunitinib was reinitiated for two cycles in those patients with an increase in TB by ≥ 10%, and again held with ≥ 10% TB reduction. This intermittent sunitinib dosing continued until Response Evaluation Criteria in Solid Tumors-defined disease progression while receiving sunitinib, or unacceptable toxicity occurred. The primary objective was feasibility, defined as the proportion of eligible patients who underwent intermittent therapy. Results Of 37 patients enrolled, 20 were eligible for intermittent therapy and all patients (100%) entered the intermittent phase. Patients were not eligible for intermittent sunitinib because of progressive disease (n = 13), toxicity (n = 1), or consent withdrawal (n = 3) before the end of cycle 4. The objective response rate was 46% after the first four cycles of therapy. The median increase in TB during the periods off sunitinib was 1.6 cm (range, −2.9 to 3.4 cm) compared with the TB immediately before stopping sunitinib. Most patients exhibited a stable sawtooth pattern of TB reduction while receiving sunitinib and TB increase while not receiving sunitinib. Median progression-free survival to date is 22.4 months (95% CI, 5.4 to 37.6 months) and median overall survival is 34.8 months (95% CI, 14.8 months to not applicable). Conclusion Periodic extended sunitinib treatment breaks are feasible and clinical efficacy does not seem to be compromised." @default.
- W2582243751 created "2017-02-03" @default.
- W2582243751 creator A5002681805 @default.
- W2582243751 creator A5008174951 @default.
- W2582243751 creator A5024482335 @default.
- W2582243751 creator A5025529463 @default.
- W2582243751 creator A5026717218 @default.
- W2582243751 creator A5031016267 @default.
- W2582243751 creator A5041898186 @default.
- W2582243751 creator A5042612556 @default.
- W2582243751 creator A5056587248 @default.
- W2582243751 creator A5082486274 @default.
- W2582243751 creator A5085460226 @default.
- W2582243751 date "2017-06-01" @default.
- W2582243751 modified "2023-10-05" @default.
- W2582243751 title "A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma" @default.
- W2582243751 cites W2008622172 @default.
- W2582243751 cites W2023952988 @default.
- W2582243751 cites W2032157317 @default.
- W2582243751 cites W2061417824 @default.
- W2582243751 cites W2098919693 @default.
- W2582243751 cites W2099088585 @default.
- W2582243751 cites W2099752220 @default.
- W2582243751 cites W2107038014 @default.
- W2582243751 cites W2110697333 @default.
- W2582243751 cites W2115125611 @default.
- W2582243751 cites W2115151884 @default.
- W2582243751 cites W2116949558 @default.
- W2582243751 cites W2117547860 @default.
- W2582243751 cites W2121515705 @default.
- W2582243751 cites W2124440635 @default.
- W2582243751 cites W2124952847 @default.
- W2582243751 cites W2139248078 @default.
- W2582243751 cites W2140088548 @default.
- W2582243751 cites W2143782771 @default.
- W2582243751 cites W2144690940 @default.
- W2582243751 cites W2149026055 @default.
- W2582243751 cites W2156728978 @default.
- W2582243751 cites W2162352067 @default.
- W2582243751 cites W2165837521 @default.
- W2582243751 cites W2484090454 @default.
- W2582243751 doi "https://doi.org/10.1200/jco.2016.71.1184" @default.
- W2582243751 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28113029" @default.
- W2582243751 hasPublicationYear "2017" @default.
- W2582243751 type Work @default.
- W2582243751 sameAs 2582243751 @default.
- W2582243751 citedByCount "31" @default.
- W2582243751 countsByYear W25822437512014 @default.
- W2582243751 countsByYear W25822437512017 @default.
- W2582243751 countsByYear W25822437512018 @default.
- W2582243751 countsByYear W25822437512019 @default.
- W2582243751 countsByYear W25822437512020 @default.
- W2582243751 countsByYear W25822437512021 @default.
- W2582243751 countsByYear W25822437512022 @default.
- W2582243751 countsByYear W25822437512023 @default.
- W2582243751 crossrefType "journal-article" @default.
- W2582243751 hasAuthorship W2582243751A5002681805 @default.
- W2582243751 hasAuthorship W2582243751A5008174951 @default.
- W2582243751 hasAuthorship W2582243751A5024482335 @default.
- W2582243751 hasAuthorship W2582243751A5025529463 @default.
- W2582243751 hasAuthorship W2582243751A5026717218 @default.
- W2582243751 hasAuthorship W2582243751A5031016267 @default.
- W2582243751 hasAuthorship W2582243751A5041898186 @default.
- W2582243751 hasAuthorship W2582243751A5042612556 @default.
- W2582243751 hasAuthorship W2582243751A5056587248 @default.
- W2582243751 hasAuthorship W2582243751A5082486274 @default.
- W2582243751 hasAuthorship W2582243751A5085460226 @default.
- W2582243751 hasConcept C126322002 @default.
- W2582243751 hasConcept C126894567 @default.
- W2582243751 hasConcept C141071460 @default.
- W2582243751 hasConcept C143998085 @default.
- W2582243751 hasConcept C2777288759 @default.
- W2582243751 hasConcept C2777472916 @default.
- W2582243751 hasConcept C2779490328 @default.
- W2582243751 hasConcept C29730261 @default.
- W2582243751 hasConcept C71924100 @default.
- W2582243751 hasConceptScore W2582243751C126322002 @default.
- W2582243751 hasConceptScore W2582243751C126894567 @default.
- W2582243751 hasConceptScore W2582243751C141071460 @default.
- W2582243751 hasConceptScore W2582243751C143998085 @default.
- W2582243751 hasConceptScore W2582243751C2777288759 @default.
- W2582243751 hasConceptScore W2582243751C2777472916 @default.
- W2582243751 hasConceptScore W2582243751C2779490328 @default.
- W2582243751 hasConceptScore W2582243751C29730261 @default.
- W2582243751 hasConceptScore W2582243751C71924100 @default.
- W2582243751 hasIssue "16" @default.
- W2582243751 hasLocation W25822437511 @default.
- W2582243751 hasLocation W25822437512 @default.
- W2582243751 hasOpenAccess W2582243751 @default.
- W2582243751 hasPrimaryLocation W25822437511 @default.
- W2582243751 hasRelatedWork W1994361201 @default.
- W2582243751 hasRelatedWork W2056402925 @default.
- W2582243751 hasRelatedWork W2072245035 @default.
- W2582243751 hasRelatedWork W2171237277 @default.
- W2582243751 hasRelatedWork W2322617799 @default.
- W2582243751 hasRelatedWork W2530207419 @default.
- W2582243751 hasRelatedWork W2544140097 @default.
- W2582243751 hasRelatedWork W3151554875 @default.